Search

Displaying results 2221 - 2230 of 10000 in total
  1. Drug

    Terazosin

    go.drugbank.com/drugs/DB01162
    ApprovedInvestigational

    Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831]. … Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate[A176837].

    Mixtures: Hytrin-7 Tabs 1mg-7 Tabs 2mg-14 Tabs 5mg, Hytrin-7 Tabs 1mg-7 Tabs 2mg-14 Tabs 5mgCategories: P-glycoprotein inhibitors, Peripheral alpha-1 blockers
  2. Drug

    Prednisone

    go.drugbank.com/drugs/DB00635
    ApprovedInvestigationalVet approved

    A synthetic anti-inflammatory glucocorticoid derived from [cortisone].[A187463] It is biologically inert and converted to [prednisolone] in the liver.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 InducersSynonyms: 1, 2-Dehydrocortisone
  3. Drug

    Flupentixol

    go.drugbank.com/drugs/DB00875
    ApprovedInvestigationalWithdrawn

    It exists in two geometric isomers, the trans(E) and pharmacologically active cis(Z) forms. … Flupentixol decanoate is one of the active ingredients found in injectable drug formulations: it is produced by esterification of cis(Z)‐flupentixol with decanoic acid.

    Categories: Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor AntagonistsProducts: Flupentixol Bayer 5 mg Filmtabletten, Fluanxol 5 mg - Filmtabletten
  4. Drug

    Terbutaline

    go.drugbank.com/drugs/DB00871
    ApprovedInvestigational

    [A230328] It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.[A230333,L32093,L32098] Terbutaline was granted FDA approval on 25 March 1974.[L32088]

    Mixtures: BİCANA 1,5 MG/5 ML + 66,5 MG/5 ML ŞURUP, 100 ML, BRELAX 1,5 MG+66,5 MG/5 ML ŞURUP, 100 MLCategories: Adrenergic beta-2 Receptor Agonists, Selective Beta 2-adrenergic Agonists
  5. Drug

    Tetraferric tricitrate decahydrate

    go.drugbank.com/drugs/DB14520
    ApprovedInvestigational

    [A25965] Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.[L9926]

    Products: FERRISITA 107,7 MG/5 ML SURUP, 150 ML
  6. Drug

    Gadoversetamide

    go.drugbank.com/drugs/DB00538
    Approved

    Gadoversetamide, marketed under the trade name OptiMARK, is a gadolinium compound used as a contrast agent in magnetic resonance imaging (MRI), particularly imaging of the brain, spine and liver.

    Categories: Compounds used in a research, industrial, or household settingProducts: OPTIMARK 500 MIKROMOL/ML IV. ENJ. ICIN COZ. ICEREN FLAKON, 15 ML, OPTIMARK 500 MIKROMOL/ML IV. ENJ. ICIN COZELTI ICEREN KUL.HAZIR SIRINGA, 15 ML
  7. Drug

    Benzyl N-[(2S)-5-(diaminomethylamino)-1-[[(2S)-4-fluoro-3-oxobutan-2-yl]amino]-1-oxopentan-2-yl]carbamate

    go.drugbank.com/drugs/DB03536
    Experimental

    Synonyms: Benzyl N-[(2S)-5-(diaminomethylamino)-1-[[(2S)-4-fluoro-3-oxobutan-2-yl]amino]-1-oxopentan-2-yl]carbamate
  8. Drug

    Linagliptin

    go.drugbank.com/drugs/DB08882
    ApprovedInvestigational

    Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557]. … Linagliptin was approved by the FDA on May 2, 2011[L9557].

    Mixtures: GLYXAMBI® 10 MG/ 5 MG, GLYXAMBI® 10 MG/ 5 MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  9. Drug

    Doxorubicin

    go.drugbank.com/drugs/DB00997
    ApprovedInvestigational

    Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. … [A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InhibitorsSynonyms: (1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside, (8S-cis)-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
  10. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. … It is a potent and selective inhibitor of JAK1 and JAK2,[A229698] which are tyrosine kinases involved in cytokine signalling and hematopoiesis.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesProducts: JAKAVİ 15 MG TABLET, 56 TABLET, JAKAVI 15 MG (TABLETS)